

# Ovarian Cancer Pathways

Patient Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Member Number: \_\_\_\_\_ Treatment Start Date: \_\_\_\_\_

ICD-10 Code: \_\_\_\_\_ Pathology: \_\_\_\_\_

Stage:  I  IA  IB  IIA  IIB  IIC  IIIA  IIIB  IIIC  IV  Recurrent

Line of Treatment:  Neoadjuvant/Pre-Op  Adjuvant/Post-Op  First Line  Second Line  Third Line  Third Line+  Maintenance

ECOG Performance Status:  0  1  2  3  4

## Biomarkers:

Germline BRCA 1?  Mutation Present  Not Reported  Wild Type (mutation absent)

Germline BRCA 2?  Mutation Present  Not Reported  Wild Type (mutation absent)

Platinum sensitive? †  Yes  No  Not Reported

Platinum-refractory or resistant?  Yes  No  Not Reported

## Adjuvant Therapy | Stage IA/B (Grade 2 or 3) or IC (Grade 1-3)

Carboplatin (Paraplatin)\* and paclitaxel (Taxol)

Carboplatin (Paraplatin)\* and dose dense paclitaxel (Taxol)

## Adjuvant or primary Therapy | Stage II, III, IV

IV paclitaxel (Taxol), Intraperitoneal (IP) cisplatin (Platinol) and IP paclitaxel (Taxol)

Carboplatin (Paraplatin)\* and paclitaxel (Taxol)

Carboplatin (Paraplatin)\* and dose dense paclitaxel (Taxol)

## Recurrent Disease | First or subsequent line of therapy (1<sup>st</sup> line+) | Platinum-sensitive†

Carboplatin (Paraplatin)\* and paclitaxel (Taxol)

Carboplatin (Paraplatin)\* and weekly paclitaxel (Taxol)

Carboplatin (Paraplatin) and gemcitabine (Gemzar)

Cisplatin (Platinol) and gemcitabine (Gemzar)

## Recurrent Disease | Second or subsequent line of therapy (2<sup>nd</sup> line+) | Platinum resistant

Bevacizumab (Avastin)

Bevacizumab (Avastin) and paclitaxel (Taxol)

Bevacizumab (Avastin) and topotecan (Hycamtin)

Docetaxel (Taxotere)

Gemcitabine (Gemzar)

Liposomal doxorubicin (Doxil or Lipodox)

Topotecan (Hycamtin)

Vinorelbine (Navelbine)

Weekly paclitaxel (Taxol)

\*Substitution of carboplatin (Paraplatin) for cisplatin (Platinol), and vice-versa, is allowed.

†Platinum sensitive is defined as recurrence >6 months after prior platinum-based therapy

